Cafepharma Today

April 29 2025 - Novartis posts better-than-expected first-quarter sales, raises full-year guidance
Novartis posts better-than-expected first-quarter sales, raises full-year guidance
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 40%
Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall
HHS lifts stop work order on Vaxart's COVID-19 trial
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Data readout puts J&J's bladder cancer drug back on track
Pharmaphorum
Tuesday, April 22, 2025 - 11:00am
tags:
JNJ, bladder cancer, TAR-200, clinical trials
Sky Labs' smart ring tops Apple Watch in AFib comparison
Pharmaphorum
Tuesday, April 22, 2025 - 10:58am
tags:
Medtech, Sky Labs, Apple, Apple Watch, atrial fibrillation, wearables, CART-I ring
Novo says it’s submitted obesity pill for FDA approval
BioPharma Dive
Monday, April 21, 2025 - 6:13pm
tags:
Novo Nordisk, Wegovy, obesity, oral Wegovy, FDA
FDA fires most negotiators for pharma user fee talks, sources say
Yahoo/Reuters
Monday, April 21, 2025 - 6:10pm
tags:
FDA, layoffs, drug reviews, user fees
Alector concludes enrollment in Phase II trial of Alzheimer’s treatment
Clinical Trials Arena
Monday, April 21, 2025 - 6:06pm
tags:
clinical trials, Alector, GSK, Alzheimer's disease, AL101
Walgreens to pay $300 million in US opioid settlement
Yahoo/Reuters
Monday, April 21, 2025 - 6:03pm
tags:
Walgreens, legal, pharmacies, opioids, opioid crisis
Dr. Oz sworn in as CMS administrator
Medtech Dive
Monday, April 21, 2025 - 6:02pm
tags:
CMS, Dr Oz, Mehmet Oz
How affirmative action ruling, federal funding cuts impact pharma and biotech
Medical Marketing and Media
Monday, April 21, 2025 - 6:00pm
tags:
pharma industry, biotech, affirmative action
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich
Stock Titan
Monday, April 21, 2025 - 5:59pm
tags:
legal, Bausch Health, Salix Pharmaceuticals, FDA, Norwich Pharmaceuticals, Xifaxin
Makary Discusses Expedited Rare Disease Approvals Pathway, ‘Public Distrust’ in New Interview
BioSpace
Monday, April 21, 2025 - 5:56pm
tags:
FDA, Marty Makary, Rare Diseases, drug approvals, regulatory
Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
BioPharma Dive
Monday, April 21, 2025 - 11:13am
tags:
Sanofi, Regeneron, Dupixent, FDA, chronic hives
AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer
Fierce Pharma
Monday, April 21, 2025 - 11:12am
tags:
AstraZeneca, Daiichi Sankyo, Enhertu, breast cancer, clinical trials
Trodelvy-Keytruda combo improves cancer trial outcomes
Investing.com
Monday, April 21, 2025 - 11:11am
tags:
Gilead Sciences, Trodelvy, Keytruda, Merck, metastatic triple-negative breast cancer
FDA rejection of extended dosing interval is another piece of bad news for Regeneron’s Eylea HD
Fierce Pharma
Monday, April 21, 2025 - 10:22am
tags:
FDA, Regeneron, Eylea, CRL
FDA moves to block biopharma employees from serving on advisory committees
Fierce Pharma
Monday, April 21, 2025 - 10:11am
tags:
FDA, advisory committees, Marty Makary, regulatory
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Stock Titan
Monday, April 21, 2025 - 10:09am
tags:
Immunovant, IMVT-1402, Eric Venker
Stealth biotech bags rights to VelaVigo bispecific in $440M deal
Fierce Biotech
Monday, April 21, 2025 - 10:04am
tags:
VelaVigo Bio, Olin Biosciences, bispecific antibodies
FDA cuts outlined in draft HHS budget
BioPharma Dive
Monday, April 21, 2025 - 10:02am
tags:
FDA, layoffs, HHS
A big moment is coming for psychedelics
Pharma Voice
Monday, April 21, 2025 - 10:01am
tags:
COMPASS Pathways, clinical trials, psilocybin, COMP360, clinical depression
How a scrapped Pfizer drug became a winner for SpringWorks
Pharma Voice
Monday, April 21, 2025 - 10:00am
tags:
SpringWorks Therapeutics, Pfizer, neurofibromatosis, mirdametinib, FDA

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

A New Glioblastoma Treatment
In the Pipeline
Streptomycin For Metastatic Cancer
In the Pipeline
The End of Disease
In the Pipeline
You Can Probably Smell That Planet From Here
In the Pipeline
Proton Pump Inhibitors Do More Than You Think
In the Pipeline
Entropy, Enthalpy, and Hydrophobicity
In the Pipeline
The Continuing Crisis, Part XII: Behold RFK Jr.'s FDA
In the Pipeline
RNA Motifs Coming Into Focus
In the Pipeline
Pharmaceutical Tariffs: The What and the How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.